Corporate News Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy Robust, double-digit organic growth in high-margin "branded pharmaceuticals" largely offsets projected decline in vaccine production. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dermapharm Holding SE published this content on 15 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 11:06:44 UTC.